Learn more in our training program.
Join our membership network.
Attend our events and collaborate.
Add your voice to our policy matters.
Get involved in our genetic registry.
Donate to our cause.
The Latino Cancer Institute (TLCI) is a nationwide community and research network dedicated to solving the issues and burden of Latino cancer.
Cancer is the leading cause of death among Hispanics/Latinos in the US. Through more public education, community resources and access to care, survival rates are improving.
Breast cancer is the leading cause of cancer death among Hispanic/Latino women. Local community outreach programs have a direct impact on woman being diagnosed and receiving treatment earlier.
Lung cancer is the leading cause of cancer death among Hispanic/Latino men. With strong public messaging, smoking rates are starting to drop in Latino communities.
Taking up the fight to change the Latino cancer landscape are the many dedicated agencies serving their communities throughout the country. Locate the one nearest you HERE.
For over 20 years, Founder Ysabel Duron has played a vital role in bringing together those dedicated to making a difference in the Latino cancer landscape. From cancer community workers and caregivers to international medical researchers and policymakers, Ysabel has forged important alliances in a field crowded with many competing interests and agendas.
It takes a savvy insider who has traveled this terrain far and wide to help the Latino cancer community at-large continue changing the landscape. TLCI offers the definitive road map.
There are currently no upcoming events.
The Latino Cancer Institute acts as a network for agencies, linking members to share knowledge and best practices. Connecting colleagues, peers and institutions is critical to The Institute’s ongoing mission to amplify and disseminate outstanding work in the cancer arena, and to support one another.
The Latino Cancer Institute provides opportunities to network, learn and collaborate with stakeholders in the cancer landscape including Latino cancer researchers.
The Latino Cancer Institute leverages our united voice at the national table to advance Latino cancer concerns including education, services, funding, and research. Our aim is to be heard, understood and included in any proposed policy.
As a nonprofit organization, we rely on philanthropy and grants in our mission to support other agencies. Your funding allows us to continue the development of new programs and tools we can share with those making a difference in the lives of Latino cancer patients, survivors, and their caregivers.
The tissue adjacent to a tumor behaves differently than areas farther away: The tumor's cancerous cells influence their surroundings, blocking the body's immune defenses and creating a sort of haven in which the tumor can grow. Treatments that target some of these pro-tumor actions are effective in a number of cancers, but only for some patients; in others, these treatments have little effect. Researchers have now developed a new approach that simultaneously targets several of these pro-tumor actions at once, which they have demonstrated can effectively reduce tumor growth across several types of cancers. Their new findings point to a potential new treatment that may benefit more patients than current therapeutic options.
Two new studies have identified a possible way to block the progression of several forms of blood cancer using a drug already in clinical trials against breast cancer.
Scientists have used deep learning to design new proteins that bind to complexes involving other small molecules like hormones or drugs, opening up a world of possibilities in the computational design of molecular interactions for biomedicine.
The American Cancer Society (ACS) today released Cancer Statistics, 2025, the organization's annual report on cancer facts and trends. The new findings show the cancer mortality rate declined by 34% from 1991 to 2022 in the United States, averting approximately 4.5 million deaths. However, this steady progress is jeopardized by increasing incidence for many cancer types, especially among women and younger adults, shifting the burden of disease. For example, incidence rates in women 50-64 years of age have surpassed those in men, and rates in women under 50 are now 82% higher than their male counterparts, up from 51% in 2002.
Researchers have shown that the amount of a protein called CD74 can indicate which people with bowel cancer may respond best to immunotherapy.
Scientists have made 'exciting,' patient-friendly advances in developing a non-toxic bacterial therapy, BacID, to deliver cancer-fighting drugs directly into tumors. This emerging technology holds promise for very safe and more effective treatment of cancers with high mortality rates, including liver, ovarian and metastatic breast cancer.
